SecBot SecBot
SECBOTREPLAY Home › Report › QTTB

QTTB · Q32 Bio Inc

Q32 Bio Inc. · 424B5 filed Apr 24, 2026 at 16:07 ET

At the news

BEARISHIMPACT 6/10

424B5 filed Apr 24, 2026 at 16:07 ET

Q32 Bio Inc. is conducting an at-the-market (ATM) equity offering of up to $75 million in common stock through Cantor Fitzgerald. The company previously raised $14.2 million under a prior ATM agreement, which has now been terminated. The new offering allows for flexible, opportunistic capital raising based on market conditions, with proceeds intended for working capital and advancing its lead drug candidate, bempikibart, into future clinical trials for alopecia areata.

  • Q32 Bio is offering up to $75,000,000 in common stock through an at-the-market (ATM) offering with Cantor Fitzgerald.
  • The company has already raised $14,200,000 under a prior ATM agreement, which has been terminated.
  • The offering is subject to market conditions, with no minimum amount required, and shares will be sold at prevailing market prices.
  • Proceeds will be used for working capital, research, clinical development, and commercialization efforts, primarily for advancing bempikibart.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access